Compare SOHU & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | LXRX |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.4M | 425.2M |
| IPO Year | 2000 | 2000 |
| Metric | SOHU | LXRX |
|---|---|---|
| Price | $15.64 | $1.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $20.00 | $3.23 |
| AVG Volume (30 Days) | 39.8K | ★ 1.6M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 5.11 | N/A |
| Revenue | ★ $576,757,000.00 | $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.06 | ★ N/A |
| Revenue Growth | N/A | ★ 1255.21 |
| 52 Week Low | $7.79 | $0.28 |
| 52 Week High | $16.45 | $1.66 |
| Indicator | SOHU | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 43.16 |
| Support Level | $14.47 | $1.12 |
| Resistance Level | $15.72 | $1.32 |
| Average True Range (ATR) | 0.45 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 89.12 | 31.54 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.